DAVID HASTINGS contact CRIBBS

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study
    David H Cribbs
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 1226 Gillespie NRF, Irvine, CA 92697, USA
    J Neuroinflammation 9:179. 2012
  2. pmc Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
    Irina Petrushina
    The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
    J Neuroinflammation 5:42. 2008
  3. pmc Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid
    Kathryn E Nichol
    Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, CA, USA
    J Neuroinflammation 5:13. 2008
  4. pmc Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention
    David H Cribbs
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 92697 4540, USA
    CNS Neurol Disord Drug Targets 9:207-16. 2010
  5. pmc Caspase-mediated degeneration in Alzheimer's disease
    David H Cribbs
    Institute for Brain Aging and Dementia, Irvine CA 92697 4540, USA
    Am J Pathol 165:353-5. 2004
  6. pmc Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice
    Irina Petrushina
    The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697 4540, USA
    J Neurosci 27:12721-31. 2007
  7. pmc Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
    David H Cribbs
    Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
    Int Immunol 15:505-14. 2003
  8. ncbi request reprint Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death
    Joseph H Su
    Institute for Brain Aging and Dementia, 1113 Gillespie Neuroscience Research Facility, University of California Irvine, 92697 4540, USA
    Neurobiol Dis 12:182-93. 2003
  9. doi request reprint Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology
    Salvatore Oddo
    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA
    J Neurosci 28:12163-75. 2008
  10. pmc Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model
    Masashi Kitazawa
    Department of Neurobiology and Behavior and Neurology, University of California, Irvine, California 92697 4545, USA
    J Neurosci 29:6132-41. 2009

Research Grants

Collaborators

Detail Information

Publications34

  1. pmc Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study
    David H Cribbs
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 1226 Gillespie NRF, Irvine, CA 92697, USA
    J Neuroinflammation 9:179. 2012
    ..This study undertakes a systematic and comprehensive analysis of brain gene expression profiles of immune/inflammation-related genes in aging and Alzheimer's disease (AD)...
  2. pmc Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
    Irina Petrushina
    The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
    J Neuroinflammation 5:42. 2008
    ..In the current study, we tested the efficacy of this vaccine configuration in amyloid precursor protein (APP) transgenic mice (Tg2576)...
  3. pmc Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid
    Kathryn E Nichol
    Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, CA, USA
    J Neuroinflammation 5:13. 2008
    ..Our objective was to determine if exercise could induce a shift from the immune profile in aged (17-19 months) Tg2576 mice to a response that reduces Abeta pathology...
  4. pmc Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention
    David H Cribbs
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, 92697 4540, USA
    CNS Neurol Disord Drug Targets 9:207-16. 2010
    ....
  5. pmc Caspase-mediated degeneration in Alzheimer's disease
    David H Cribbs
    Institute for Brain Aging and Dementia, Irvine CA 92697 4540, USA
    Am J Pathol 165:353-5. 2004
  6. pmc Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice
    Irina Petrushina
    The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697 4540, USA
    J Neurosci 27:12721-31. 2007
    ....
  7. pmc Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid
    David H Cribbs
    Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, USA
    Int Immunol 15:505-14. 2003
    ....
  8. ncbi request reprint Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death
    Joseph H Su
    Institute for Brain Aging and Dementia, 1113 Gillespie Neuroscience Research Facility, University of California Irvine, 92697 4540, USA
    Neurobiol Dis 12:182-93. 2003
    ..These findings suggest that Fas-FasL interactions may contribute to mechanisms of neuronal loss and neuritic degeneration in AD...
  9. doi request reprint Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology
    Salvatore Oddo
    Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92697, USA
    J Neurosci 28:12163-75. 2008
    ..These data highlight the critical role CHIP plays as a link between Abeta and tau and identify CHIP as a new potential target not only for AD but for other neurodegenerative disorders characterized by tau accumulation...
  10. pmc Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model
    Masashi Kitazawa
    Department of Neurobiology and Behavior and Neurology, University of California, Irvine, California 92697 4545, USA
    J Neurosci 29:6132-41. 2009
    ..These findings provide support for the hypothesis that Abeta is one of the key pathogenic components in IBM pathology and subsequent skeletal muscle degeneration...
  11. ncbi request reprint Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome
    Salvatore Oddo
    Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, CA 92697, USA
    Neuron 43:321-32. 2004
    ..These findings indicate that Abeta immunization may be useful for clearing both hallmark lesions of AD, provided that intervention occurs early in the disease course...
  12. doi request reprint Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation
    Anna Parachikova
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA 92697 4545, USA
    J Alzheimers Dis 21:527-42. 2010
    ....
  13. ncbi request reprint Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles
    Salvatore Oddo
    Departments of Neurobiology and Behavior and Neurology, and Institute for Brain Aging and Dementia, University of California, Irvine, California 92697, USA
    J Biol Chem 281:39413-23. 2006
    ..Notably, reducing soluble Abeta alone did not improve the cognitive phenotype in mice with plaques and NFTs. Our results show that Abeta immunotherapy reduces soluble tau and ameliorates behavioral deficit in old transgenic mice...
  14. pmc A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain
    Floyd Sarsoza
    Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697, USA
    Acta Neuropathol 118:505-17. 2009
    ....
  15. pmc Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta
    Vitaly Vasilevko
    The Institute for Memory Impairments and Neurological Disorders, University of California, Irvine 92697 4540, USA
    Neurobiol Dis 39:301-10. 2010
    ..Our findings indicate that prolonged immunization results in distinctive temporal changes in antibody profiles, which may be important for other experimental and clinical settings...
  16. ncbi request reprint Beta-amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome
    Elizabeth Head
    Institute for Brain Aging and Dementia, University of California at Irvine, Irvine, CA 92697 4540, USA
    Neurosci Lett 330:99-103. 2002
    ..Abeta within or around neurons in addition to contributing to NFT formation may also trigger apoptotic pathways. Caspase activation may lead to the cleavage of critical cellular proteins and neuronal cell death associated with DS...
  17. ncbi request reprint Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta
    Elizabeth Head
    Institute for Brain Aging and Dementia, Department of Neurology, University of California, 1259 Gillespie Neuroscience Research Facility, Irvine, CA 92697 4540, USA
    Vaccine 24:2824-34. 2006
    ..A nonsignificant increase in CSF Abeta(1-40) and decrease in Abeta(1-40/1-42) in cortex was detected. Canines may be a useful system for testing an Abeta vaccine...
  18. ncbi request reprint Relapsing polychondritis with features of dementia with Lewy bodies
    Elizabeth Head
    Institute for Brain Aging and Dementia, University of California, Irvine, CA 92697 4540, USA
    Acta Neuropathol 112:217-25. 2006
    ..This study demonstrates that qualitatively similar inflammation-associated neurodegeneration is present in widespread regions of the brain in a RP case presenting clinically as DLB...
  19. ncbi request reprint Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice
    Vitaly Vasilevko
    The Institute for Brain Aging and Dementia, University of California, Irvine, Irvine, California 92697 4540, USA
    J Neurosci 27:13376-83. 2007
    ..Thus, approaches that deliver immunotherapy to the brain may be more effective at clearing Abeta than immunization strategies in which the majority of the antibodies are in the periphery...
  20. pmc Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy
    Vitaly Vasilevko
    Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA
    Ann N Y Acad Sci 1207:58-70. 2010
    ..Thus, there is a critical need for new strategies that improve BBB function and limit the development of β-amyloidosis in the cerebral vasculature...
  21. ncbi request reprint The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain
    Ming Zhao
    Institute for Brain Aging and Dementia, University of California Irvine, Irvine, California, USA
    Neurochem Res 28:307-18. 2003
    ..Our findings suggest that the TNF death receptor pathway and caspases are activated in the early stages of neuronal degeneration in AD...
  22. ncbi request reprint Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice
    Irina Petrushina
    The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, Irvine USA
    Neurosci Lett 338:5-8. 2003
    ..Our results suggest that APP/Tg2576 and major histocompatibilty complex-matched parental strains are not expressing IgG2a, producing instead IgG2c anti-Abeta antibodies...
  23. ncbi request reprint Mimotopes of conformational epitopes in fibrillar beta-amyloid
    Goar Gevorkian
    Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico
    J Neuroimmunol 156:10-20. 2004
    ....
  24. ncbi request reprint Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide
    Michael G Agadjanyan
    Institute for Molecular Medicine, Department of Immunology, Huntington Beach, CA 92647, USA
    J Immunol 174:1580-6. 2005
    ..New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial...
  25. pmc Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch
    Anahit Ghochikyan
    Department of Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647 3652, USA
    Vaccine 24:2275-82. 2006
    ..These results suggest that switching from Alum to Quil A would be beneficial for AD patients because anti-Abeta antibody production was enhanced without changing the initially generated and likely beneficial Th2-type humoral response...
  26. pmc Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates
    Anahit Ghochikyan
    The Institute for Molecular Medicine, Department of Immunology, Huntington Beach, California, USA
    DNA Cell Biol 25:571-80. 2006
    ..New preclinical trials in AD mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse immune response that occurred in the first clinical trial...
  27. pmc Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy
    Nina Movsesyan
    Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, California, United States of America
    PLoS ONE 3:e2124. 2008
    ....
  28. pmc Amyloid-beta peptide binds to microtubule-associated protein 1B (MAP1B)
    Goar Gevorkian
    Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Apartado Postal 70228, Cuidad Universitaria, Mexico DF, CP 04510, Mexico
    Neurochem Int 52:1030-6. 2008
    ..This interaction may explain, in part, the loss of neuronal cytoskeletal integrity, impairment of microtubule-dependent transport and synaptic dysfunction observed previously in Alzheimer's disease...
  29. ncbi request reprint Novel approaches for immunotherapeutic intervention in Alzheimer's disease
    Vitaly Vasilevko
    The Institute for Brain Aging and Dementia, University of California Irvine, Irvine, CA 92697 4540, United States
    Neurochem Int 49:113-26. 2006
    ....
  30. ncbi request reprint Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease
    Milan Fiala
    Department of Medicine, UCLA VA School of Medicine, Los Angeles, CA, USA
    J Alzheimers Dis 11:457-63. 2007
    ..Finally, peripheral blood leukocytes are a superior model system for investigation of innate immune dysfunction in Alzheimer's disease...
  31. ncbi request reprint Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant
    Dmitri Loukinov
    National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
    J Cell Biochem 98:1037-43. 2006
    ..This is the first report demonstrating the feasibility of vaccination with a cancer associated epigenetic regulator for the induction of tumor inhibition...
  32. pmc Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene
    Anahit Ghochikyan
    The Institute for Molecular Medicine, Department of Immunology, Huntington Beach, USA
    Eur J Immunol 33:3232-41. 2003
    ..The DNA minigene-induced anti-Abeta antibodies bound to Abeta plaques in brain tissue from an Alzheimer's disease patient demonstrating functional activity of the antibodies and the potential for therapeutic efficacy...
  33. pmc Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers
    Grigor Mamikonyan
    Department of Immunology, The Institute for Molecular Medicine, Huntington Beach, California 92647, USA
    J Biol Chem 282:22376-86. 2007
    ....
  34. pmc Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites
    Anahit Ghochikyan
    Department of Molecular Immunology, Institute for Molecular Medicine, Huntington Beach, CA 92647, USA
    J Immunol 178:566-73. 2007
    ..These cytolytic responses were observed across a wide range of different mouse cancers including mammary adenocarcinoma, glioma, leukemia, and mastocytoma...

Research Grants18

  1. Combining AD epitope vaccine with innate immunity
    DAVID HASTINGS contact CRIBBS; Fiscal Year: 2010
    ..In current project we propose to generate safe and effective epitope vaccine that may prevent/reduce development of Alzheimer's disease pathology in pre-symptomatic people diagnosed with early-stage AD. ..
  2. Combining AD epitope vaccine with innate immunity
    David Cribbs; Fiscal Year: 2009
    ..In current project we propose to generate safe and effective epitope vaccine that may prevent/reduce development of Alzheimer's disease pathology in pre-symptomatic people diagnosed with early-stage AD. ..
  3. Multiple Approaches to Abeta Vaccination in Animal Models
    David Cribbs; Fiscal Year: 2009
    ..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..
  4. Multiple Approaches to Abeta Vaccination in Animal Models
    David Cribbs; Fiscal Year: 2007
    ..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..
  5. Combining AD epitope vaccine with innate immunity
    David Cribbs; Fiscal Year: 2007
    ..We believe that this approach will provide a more comprehensive assessment of the overall efficacy of immunotherapy as a potential clinical approach for treating AD. ..
  6. Multiple Approaches to ABeta Vaccination in Animal Mode*
    David Cribbs; Fiscal Year: 2005
    ..Therefore, both prophylactic and therapeutic vaccination will be tested. ..
  7. Multiple Approaches to Abeta Vaccination in Animal Models
    DAVID HASTINGS CRIBBS; Fiscal Year: 2010
    ..Additional studies will focus on identifying risk factors associated with immunizing elderly patients and developing protective therapies to eliminate these risk factors. ..